Using genetic tests to guide the prescribing of post-PCI P2Y12 inhibitors can reduce ischemic events in patients with coronary artery disease, according to results of a new meta-analysis. Its authors ...
Data on CAY001, a First-in-Class, Polyphosphate (polyP)-Based Therapy, Show Promise in Bypassing P2Y12 Inhibition to Restore Normal Clotting Function These early data are promising as they demonstrate ...
(UPDATED) The much-awaited TAILOR-PCI trial did not meet its primary outcome to show that, in loss-of-function carriers with ACS or stable CAD post-PCI patients, using a genotype-guided oral P2Y12 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results